Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided content aligns with the FDA-approved label’s boxed warning and TD-related warnings for metoclopramide (including GIMOTI). The evaluation does not introduce unsupported or contradictory safety claims.
Category Scores
Accurate Statements
WARNING: TARDIVE DYSKINESIA
Boxed Warning (TARDIVE DYSKINESIA) and Section 5.1 (Tardive Dyskinesia) state metoclopramide (including GIMOTI) can cause TD, risk increases with duration/cumulative dose, and provide discontinuation and duration limits.
Label states metoclopramide (including GIMOTI) can cause tardive dyskinesia; TD risk increases with duration and cumulative dose; contraindicated in patients with a history of tardive dyskinesia; discontinue immediately if tardive dyskinesia occurs; avoid treatment longer than 12 weeks.
Boxed Warning (TARDIVE DYSKINESIA); Contraindications (Section 4); Warnings and Precautions (5.1); Dosage guidance in Section 2.2 limiting treatment to 12 weeks.
Warnings and precautions include prevention/mitigation/monitoring steps such as shortest duration, periodic reassessment, and immediate discontinuation if TD signs/symptoms develop.
Section 5.1 (Tardive Dyskinesia) lists prevention/mitigation/monitoring for TD: shortest duration with periodic reassessment; immediately discontinue if TD occurs; avoid >12 weeks and monitor if unavoidable.
Contraindication in patients with a history of TD or dystonic reaction to metoclopramide.
Section 4 (CONTRAINDICATIONS) includes history of TD or dystonic reaction to metoclopramide.
Unsupported Statements
Contradictions
Important Omissions
The response/evaluation does not mention the specific additional TD-related interaction/avoidance instruction (e.g., avoiding concomitant antipsychotics due to potential additive effects) that appears in Section 5.1 and Section 7.1.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are confined to the boxed warning/TD risk framework and do not introduce incorrect dosing, contraindications, or risk statements beyond what the label supports.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Does not cover all TD-related boxed-warning/precaution elements in the provided excerpt (e.g., avoidance of concomitant antipsychotics).
Suggested Improvement
If addressing TD warning comprehensively, also include the label’s TD prevention/monitoring points from Section 5.1 (including avoidance of concomitant antipsychotics) and related interaction content from Section 7.1.